CN118139624A - 治疗乳腺癌的方法 - Google Patents

治疗乳腺癌的方法 Download PDF

Info

Publication number
CN118139624A
CN118139624A CN202280039309.4A CN202280039309A CN118139624A CN 118139624 A CN118139624 A CN 118139624A CN 202280039309 A CN202280039309 A CN 202280039309A CN 118139624 A CN118139624 A CN 118139624A
Authority
CN
China
Prior art keywords
breast cancer
patients
olaparib
survival
years
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039309.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·菲尔丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN118139624A publication Critical patent/CN118139624A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202280039309.4A 2021-06-02 2022-05-31 治疗乳腺癌的方法 Pending CN118139624A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02
US63/195795 2021-06-02
PCT/EP2022/064697 WO2022253800A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Publications (1)

Publication Number Publication Date
CN118139624A true CN118139624A (zh) 2024-06-04

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039309.4A Pending CN118139624A (zh) 2021-06-02 2022-05-31 治疗乳腺癌的方法

Country Status (12)

Country Link
US (1) US20240269135A1 (https=)
EP (1) EP4346828A1 (https=)
JP (1) JP2024520142A (https=)
KR (1) KR20240016344A (https=)
CN (1) CN118139624A (https=)
AU (1) AU2022286616A1 (https=)
BR (1) BR112023025003A2 (https=)
CA (1) CA3220751A1 (https=)
CL (1) CL2023003533A1 (https=)
IL (1) IL308684A (https=)
MX (1) MX2023014420A (https=)
WO (1) WO2022253800A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
JP2024520142A (ja) 2024-05-21
CA3220751A1 (en) 2022-12-08
MX2023014420A (es) 2024-04-23
WO2022253800A1 (en) 2022-12-08
US20240269135A1 (en) 2024-08-15
KR20240016344A (ko) 2024-02-06
BR112023025003A2 (pt) 2024-02-20
AU2022286616A1 (en) 2024-01-18
IL308684A (en) 2024-01-01
EP4346828A1 (en) 2024-04-10
CL2023003533A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
De Placido et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
Sainato et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)
Martín et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Edwards et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
Malandrino et al. Prognostic markers of survival after combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma
Guo et al. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study
Wang et al. Primary testicular lymphoma: experience with 13 cases and literature review
Borgers et al. Melanoma metastases to the adrenal gland are highly resistant to immune checkpoint inhibitors
Yu et al. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
Yoshihama et al. Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer
CN118139624A (zh) 治疗乳腺癌的方法
Wang et al. Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
Cui et al. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study
Grazia et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer
Team Pertuzumab (Perjeta)
Psyrri Exceptional Response to Copanlisib in a Heavily Pretreated Patient WithPIK3CA-Mutated Metastatic Breast Cancer
Mayer et al. Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience
Kishida et al. LH–RH agonist monotherapy for androgen receptor-positive recurrent and/or metastatic salivary gland cancer: a retrospective study
Furukawa et al. Treatment of malignant primary cardiac tumors requires attention to cardiovascular complications: a single-center, retrospective study
Luján et al. Chemotherapy-associated neutropenia with same-day versus next-day pegfilgrastim in outpatient chemotherapy: solid tumour cohort study
US20250186584A1 (en) Methods of treating biliary tract cancer using anti-pd-l1 antibody in combination with chemotherapy
Tian et al. The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study
Guo et al. Long‑term survival of a patient with advanced lung cancer treated with targeted therapy and anti‑PD‑1 immunotherapy as multi‑line therapy: A case report
Singh et al. ISMPO Guidelines for Diagnosis and Management of Early Breast Cancer
Sym et al. A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination